MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

PDF Version NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commer

MiNK TherapeuticsApr 30 12:00

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

PDF Version MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activ

MiNK TherapeuticsApr 8 12:00

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno

BenzingaApr 6 01:06

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N

BenzingaApr 5 20:09

All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy

Yahoo FinanceMar 26 00:00

Buy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Moves

TipRanksMar 25 09:48